Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e53

Raya Leibowitz-Amit

doi:10.1016/j.eururo.2019.03.013

Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e53

Raya Leibowitz-Amit^*

^*Corresponding author for this work

Oncology

Sheba Medical Center at Tel Hashomer

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e19
Journal	European Urology
Volume	76
Issue number	1
DOIs	https://doi.org/10.1016/j.eururo.2019.03.013
State	Published - Jul 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2019.03.013

Cite this

Leibowitz-Amit, R. (2019). Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e53. European Urology, 76(1), e19. https://doi.org/10.1016/j.eururo.2019.03.013

@article{38d9f916845c49ad9c65590c0345d06a,

title = "Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e53",

author = "Raya Leibowitz-Amit",

year = "2019",

month = jul,

doi = "10.1016/j.eururo.2019.03.013",

language = "אנגלית",

volume = "76",

pages = "e19",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "1",

}

Leibowitz-Amit, R 2019, 'Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e53', European Urology, vol. 76, no. 1, pp. e19. https://doi.org/10.1016/j.eururo.2019.03.013

Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e53. / Leibowitz-Amit, Raya.
In: European Urology, Vol. 76, No. 1, 07.2019, p. e19.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re

T2 - The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e53

AU - Leibowitz-Amit, Raya

PY - 2019/7

Y1 - 2019/7

UR - http://www.scopus.com/inward/record.url?scp=85066168811&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2019.03.013

DO - 10.1016/j.eururo.2019.03.013

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 30928161

AN - SCOPUS:85066168811

SN - 0302-2838

VL - 76

SP - e19

JO - European Urology

JF - European Urology

IS - 1

ER -

Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e53

UN SDGs

Access to Document

Other files and links

Cite this